14/12/2020
BIOLAN HEALTH has developed a rapid serological test for the detection of antibodies against SARS-CoV-2, the virus that causes COVID-19.
A new serological test to detect IgG and IgM antibodies against SARS-CoV-2 has been developed by BIOLAN HEALTH. The test is quick and easy to use, from a drop of capillary blood, will allow identify people who are or have been infected by the virus that causes COVID-19.
A very differentiating feature of the BIOLAN HEALTH test is that it allows the detection of antibodies directed against the SARS-CoV-2 zone responsible for the entry of the virus into the cell, the receptor binding region (RBD) of the Spike-1 protein. These antibodies that target the RBD have the potential to be neutralizers against SARS-CoV-2 and therefore may prevent future infections. Therefore, the new serological test of BIOLAN HEALTH, will allow to identify persons who have neutralising antibodies against SARS-CoV-2 and therefore can be "potentially" immune.
This means that, in addition to being a useful tool for carrying out epidemiological studies to gain a better understanding of the incidence and spread of the virus, it can also be a very useful tool for assessing the effectiveness of vaccines.
